Screening for MAFLD: who, when and how?

Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals

(2022) Kai En Chan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes?

(2022) Eda Kaya et al.   Hepatobiliary Surgery and Nutrition

Global multi-stakeholder endorsement of the MAFLD definition

(2022) Nahum Méndez-Sánchez et al.   Lancet Gastroenterology & Hepatology

Detangling the interrelations between MAFLD, insulin resistance, and key hormones

(2022) Shreya C. Pal et al.   Hormones-International Journal of Endocrinology and Metabolism

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight

(2022) Mohammed Eslam et al.   Nature Reviews Gastroenterology & Hepatology

Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

(2021) Yin-Lian Wu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD

(2021) Vy H. Nguyen et al.   Clinical Gastroenterology and Hepatology

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update

(2021) Jawaher Alharthi et al.   Journal of Clinical and Translational Hepatology

Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease

(2021) Bing Guo et al.   JOURNAL OF HEPATOLOGY

Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD

(2021) Liang-Jie Tang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

(2020) Maryam Akbari et al.   Lipids in Health and Disease

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity

(2020) Amedeo Lonardo et al.   Annals of Hepatology

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

(2020) Qing Ye et al.   Lancet Gastroenterology & Hepatology

Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health

(2020) Mohammed Eslam et al.   Lancet Gastroenterology & Hepatology

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

(2020) Zobair M. Younossi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Concordance of MAFLD and NAFLD diagnostic criteria in “real‐world” data

(2020) Giovanni Targher   LIVER INTERNATIONAL

Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography

(2020) Mikael F. Forsgren et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis

(2020) Karolina Jakubczyk et al.   Nutrients

Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index

(2020) Fatih Eren et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   Hepatology International

Effects of resveratrol supplementation on liver enzymes: A systematic review and meta‐analysis of randomised controlled trials

(2020) Mina Darand et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients

(2020) Mohammed Eslam et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD

(2020) Yusuf Yilmaz et al.   Expert Review of Gastroenterology & Hepatology

The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease

(2020) Nahum Mendez-Sanchez et al.   Lancet Gastroenterology & Hepatology

Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2020) Shumin Wei et al.   COMPLEMENTARY THERAPIES IN MEDICINE

Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts.

(2019) Margarita Papatheodoridi et al.   CURRENT PHARMACEUTICAL DESIGN

Implications of the introduction of new criteria for the diagnosis of gestational diabetes: a health outcome and cost of care analysis

(2019) Thomas J Cade et al.   BMJ Open

Lean NAFLD : A Distinct Entity Shaped by Differential Metabolic Adaptation

(2019) Fei Chen et al.   HEPATOLOGY

The management of incidental fatty liver found on imaging. What do we need to do?

(2018) Nahum Méndez-Sánchez et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

More Evidence for the Genetic Susceptibility of Mexicans Population to Nonalcoholic Fatty Liver Disease through PNPLA3

(2018) Paulina Chinchilla-López et al.   Annals of Hepatology

Lifestyle interventions for patients with nonalcoholic fatty liver disease

(2018) Tian-Tian Zou et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease

(2018) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis

(2018) Samuel J. Daniels et al.   HEPATOLOGY

Serum Osteocalcin Levels in Children With Nonalcoholic Fatty Liver Disease

(2018) Saleh Amin et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Nonalcoholic Fatty Liver Disease

(2018) Xiao Jing Wang et al.   ANNALS OF INTERNAL MEDICINE

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Systematic Review and Meta-Analysis Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis

(2017)   Journal of Gastrointestinal and Liver Diseases

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Clinical guidelines of non-alcoholic fatty liver disease: A systematic review

(2016) Jin-Zhou Zhu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Biomarkers in Nonalcoholic Fatty Liver Disease

(2016) Manuela G Neuman et al.   Canadian Journal of Gastroenterology and Hepatology

Accuracy of MR Imaging–estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease

(2015) An Tang et al.   RADIOLOGY

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

(2013) Yasar Colak et al.   MEDICAL SCIENCE MONITOR

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis

(2012) John Zhong Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography

(2012) Robert P. Myers et al.   LIVER INTERNATIONAL

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

(2011) Silvia Sookoian et al.   HEPATOLOGY

SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism

(2010) Bhaskar Ponugoti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Amy G. Shah et al.   Clinical Gastroenterology and Hepatology

Non-Alcoholic Fatty Liver Disease in Older People

(2009) James Frith et al.   GERONTOLOGY

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS